Other: Measurement of drug (Adalimumab/Infliximab) ( DrugBank: Adalimumab, Infliximab )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
96	クローン病	1
97	潰瘍性大腸炎	1

96. クローン病

---

臨床試験数 : 2,400 /  薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01960426 (ClinicalTrials.gov)	April 2014	25/9/2013	Evaluation of Health Costs and Resource Utilization	A Randomized Evaluation of Health Costs and Resource Utilization Comparing Testing-Based Therapy to Empiric Dose Intensification for the Management of Inflammatory Bowel Disease.	Ulcerative Colitis;Crohn's Disease	Other: Measurement of drug (Adalimumab/Infliximab);Other: Intensify treatment with the existing drug	University of Western Ontario, Canada	Prometheus Laboratories	Terminated	18 Years	N/A	Both	51	Phase 4	United States

97. 潰瘍性大腸炎

---

臨床試験数 : 2,527 /  薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01960426 (ClinicalTrials.gov)	April 2014	25/9/2013	Evaluation of Health Costs and Resource Utilization	A Randomized Evaluation of Health Costs and Resource Utilization Comparing Testing-Based Therapy to Empiric Dose Intensification for the Management of Inflammatory Bowel Disease.	Ulcerative Colitis;Crohn's Disease	Other: Measurement of drug (Adalimumab/Infliximab);Other: Intensify treatment with the existing drug	University of Western Ontario, Canada	Prometheus Laboratories	Terminated	18 Years	N/A	Both	51	Phase 4	United States